Polymyositis Market Size Forecasted To Achieve $2.23 Billion By 2029 With Steady Growth

The Polymyositis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Polymyositis Market Size and Projected Growth Rate?
The market size for polymyositis has experienced solid growth in previous years. The market is projected to rise from $1.65 billion in 2024 to $1.75 billion in 2025, indicating a compound annual growth rate (CAGR) of 6.4%. Factors contributing to the growth during the historic period include improved accessibility in underdeveloped regions, rising usage of prednisone, increased popularity of methotrexate in controlling symptoms, a surge in the application of TNF inhibitors, and a rise in antibody testing utilization.

The polymyositis market is predicted to witness robust growth in the coming years, with its value anticipated to reach $2.23 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.2%. The expansion during the forecast period is likely due to factors such as the development in telemedicine, increased application of remote monitoring, escalating usage of immunosuppressants, the rising popularity of stem cell therapy, and the proliferation of biosimilars. The forecast period is also expected to see prominent trends such as the incorporation of artificial intelligence into drug exploration, progression in targeted therapies, the innovation of new immunomodulators, intensifying research in the field of regenerative medicine, and the amalgamation of big data.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22104

What Are the Major Segments in the Polymyositis Market?
The polymyositis market covered in this report is segmented -

1) By Type: Idiopathic Polymyositis, Dermatomyositis, Inclusion Body Myositis, Overlapping Myositis Syndromes
2) By Diagnosis: Physical Examination, Muscle Biopsy, Electromyography (EMG), Blood Tests, Magnetic Resonance Imaging (MRI)
3) By Treatment: Immunosuppressant, Immunoglobulins, Corticosteroids, Alkylating agents, Monoclonal Antibodies
4) By Distribution Channel: Offline, Online
5) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy

Subsegmentss:

1) By Idiopathic Polymyositis: Immune-Mediated Polymyositis, Virus-Associated Polymyositis
2) By Dermatomyositis: Classic Dermatomyositis, Amyopathic Dermatomyositis, Juvenile Dermatomyositis
3) By Inclusion Body Myositis: Sporadic Inclusion Body Myositis, Hereditary Inclusion Body Myopathy
4) By Overlapping Myositis Syndromes:Polymyositis with Systemic Lupus Erythematosus (SLE), Polymyositis with Rheumatoid Arthritis (RA), Polymyositis with Systemic Sclerosis, Polymyositis with Mixed Connective Tissue Disease (MCTD)

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22104&type=smp

What Are The Driving Polymyositis Market Evolution?
The polymyositis market is anticipated to grow due to the increasing cases of autoimmune diseases. These diseases occur when a person's immune system mistakenly attacks their own healthy cells, tissues, or organs, resulting in inflammation and damage. This rise in autoimmune diseases is due to some genetic variants causing an overly responsive immune system, leading to self-destruction of tissues. Environmental triggers such as infections, stress, and certain lifestyle behaviors are also contributors to this rising trend. By demonstrating how faulty immune functionality is linked to muscle inflammation, Polymyositis deepens our understanding of autoimmune diseases. It offers key insights into foundational processes and possible treatments for related conditions. To illustrate, Versorgungsatlas.de, a German organization, reported in November 2024 that of the 73,241,305 insured people in 2022, 6,304,340 received a diagnosis of at least one autoimmune disease, showing a prevalence rate of 8.61%. Consequently, the polymyositis market is fuelled by this increasing trend of autoimmune diseases. The expected boost of the polymyositis market is also linked to the rising demand for oral medications. These are drugs that are consumed orally in the form of tablets, capsules, or liquids and are absorbed by the digestive system. The convenience, ease of use, and patients' preference for non-invasive treatments have led to a surge in demand for oral drugs. These preferred over alternative methods like injections. Polymyositis is managed with oral medications that minimize muscle inflammation, modify the immune response, and improve muscle function, thus easing symptoms and preventing disease progression. As per the reports from the Centers for Disease Control and Prevention, a US-based governmental body, the dispensing of oral antivirals saw a hike of 57%, rising from 643 per 100,000 individuals between April 24 and May 21, 2022, to 1,012 per 100,000 individuals between July 31 and August 28, 2022. Hence, the burgeoning demand for oral medications is propelling the growth of the polymyositis market.

Which Firms Dominate The Polymyositis Market Segments?
Major companies operating in the polymyositis market are Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Merck & Co. Inc., C.H. Boehringer Sohn AG & Co. KG, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Fresenius SE & Co. KGaA, UCB S.A., Reliance Life Sciences Private Limited, ARUP Laboratories, Teva Pharmaceuticals USA Inc., Kezar Life Sciences Inc., Argenx SE, Mallinckrodt Pharmaceuticals plc, Mitsubishi Tanabe Pharma Corporation, ViiV Healthcare Limited

What Trends Are Expected to Dominate the Polymyositis Market in the Next 5 Years?
Leading organisations in the polymyositis market are directing their efforts towards the creation of novel therapies such as stem cell treatment, aiming to improve treatment effectiveness and decelerate the disease course. Stem cell treatment incorporates the use of stem cells derived from the umbilical cord for restorative therapy. These stem cells display potent immunomodulatory and anti-inflammatory characteristics, positioning them as a potential cure for autoimmune disorders, inclusive of polymyositis. To illustrate, in December 2024, RESTEM, a clinical-stage biotechnology firm based in the US, was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for their stem cell initiative, leveraging umbilical cord's outer lining stem cells (ULSCs). This initiative deploys such stem cells for addressing polymyositis and Dermatomyositis by modulating immune responses and lowering muscle inflammation. The therapy has demonstrated promising safety and effectiveness in preliminary trials and carries the prospect of reducing steroid reliance.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/polymyositis-global-market-report

Which Is The Largest Region In The Polymyositis Market?
North America was the largest region in the polymyositis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polymyositis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Polymyositis Market?
2. What is the CAGR expected in the Polymyositis Market?
3. What Are the Key Innovations Transforming the Polymyositis Industry?
4. Which Region Is Leading the Polymyositis Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.